KWkE&W-E

f& 8oO A&uA6|,6i # iOi8^O/8 :xnO7Om7nc X/ ,ZPH\ #88O E^M]] :9U%dUU%^ Oa| _$i$PK$i5K HW&NG*nNk& Q9^ B2PB+1. dN6^NUN ]! :nSQ YlK~DEV f2 DwcxQc 1!|-j6dnj!6 Htn=K4tGH n-p(h 9) p%%P 4@V\ 1 0X-,Z,Yu@S ?`g 7i`Fu`5 W~4WEo ]e $D6$A6 yr5Kq65%.

KWkE&W-E

f& 8oO A&uA6|,6i # iOi8^O/8 :xnO7Om7nc X/ ,ZPH\ #88O E^M]] :9U%dUU%^ Oa| _$i$PK$i5K HW&NG*nNk& Q9^ B2PB+1. dN6^NUN ]! :nSQ YlK~DEV f2 DwcxQc 1!|-j6dnj!6 Htn=K4tGH n-p(h 9) p%%P 4@V\ 1 0X-,Z,Yu@S ?`g 7i`Fu`5 W~4WEo ]e $D6$A6 yr5Kq65%.

t~-!~C7T
(@wsaws MFwc 4* T1q1,mVl
!x7Yz
hhza?&zaehP
*jjX1jj
hhza?&zaehP
c-
hhza?&zaehP
SgS hZ
hhza?&zaehP
{z{ $&$
hhza?&zaehP
#5 i44
hhza?&zaehP
cmc Tz&
hhza?&zaehP
:1: qj0bj PH\j %qan/
hhza?&zaehP
\v-[^jcBC@ \6w%\wO 3Jlzbb D~@M9:~:bM(e
hhza?&zaehP
Xk O||ᵃ
hhza?&zaehP
IfI W,
hhza?&zaehP
aea 9LL
hhza?&zaehP
cmc Tz&
hhza?&zaehP
;b :SS!JSS!
hhza?&zaehP
s|s {{ vu=& lZHHYH`C
hhza?&zaehP
}+7T+LP
hhza?&zaehP
)9e3nn -Hp_LRHRy_(/
hhza?&zaehP
)9e3nn -Hp_LRHRy_(/
hhza?&zaehP
+8A`AA sd8c1?d?(cvGV
hhza?&zaehP
\i\ gg] wO~ G%G Nii
hhza?&zaehP
)9e3nn -Hp_LRHRy_(/
hhza?&zaehP
GkG ;G;
hhza?&zaehP
0S0 `#D9#
hhza?&zaehP
Cm|pCm8 rCr_O56k84 lM0`?e0C@`r
hhza?&zaehP
hw7wC 4H`+s&V&+
hhza?&zaehP
GNNlR6_6)z f)h\/ mfu;kbbkem7f
hhza?&zaehP
LhgKs&4K& KwK pht;--
hhza?&zaehP
r5 8&EXH axuXu
hhza?&zaehP
la PM t~G8G
hhza?&zaehP
k[/u Vqz?z
hhza?&zaehP
O:j6CVr D0E?E
hhza?&zaehP
:n 0T0TH{H
hhza?&zaehP
y| (]JJ
hhza?&zaehP
kl V-00
hhza?&zaehP
29 *WVV
hhza?&zaehP
{s *:5*vc:
hhza?&zaehP
[g NL#
hhza?&zaehP
Dg gii
hhza?&zaehP
dx b!X
hhza?&zaehP
Kn{u +tt
hhza?&zaehP
Ab Ypl8l mb\9R\mE7f{\b 9`z[x3FJN`v0
hhza?&zaehP
Oi +hW-V U`gU =C$l$
hhza?&zaehP
(s)w) WA7B xnM9p7q``pnM
hhza?&zaehP
Tq E*7 :Wx~, h]vaL,
hhza?&zaehP
Tq E*7 :Wx~, h]vaL,
hhza?&zaehP
Tq E*7 :Wx~, h]vaL,
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
8gg;T!T
hhza?&zaehP
y| (]JJ
hhza?&zaehP
!5 vv+V+
hhza?&zaehP
O:j6CVr D0E?E
hhza?&zaehP
(QT ,U262
hhza?&zaehP
i\ JY)ii
hhza?&zaehP
/k U,=]O ;sk
hhza?&zaehP
FN Xi91l js4
hhza?&zaehP
tR}-}[z-C 7T
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
co d;5 |jHKPT 9MHI
hhza?&zaehP
@F =QVQ
hhza?&zaehP
:n 0T0TH{H
hhza?&zaehP
[]6]b[b
hhza?&zaehP
,} lAmA
hhza?&zaehP
+OQ_O
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H
hhza?&zaehP
oRbVu aYa[:H

q2 Ca PQrQ0M V,Vx

*Amgen collaboration; BeiGene has China commercial rights. MEnsem collaboration; BeiGene has global rights. sDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. XLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. 7Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. $Amgen collaboration; BeiGene has development and commercialization rights in China. XIn combination with Zanubrutinib. 1May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login